natgillin/translations-raw huggingface dataset:
In a randomised, 48-week double-blind, controlled study of tenofovir disoproxil 245 mg (as fumarate) in adult patients co-infected with HIV-1 and chronic hepatitis B with prior lamivudine experience (study ACTG 5127), the mean serum HBV DNA levels at baseline in patients randomised to the tenofovir arm were 9.45 log10 copies/ml (n = 27).
V randomizirani, 48-tedenski dvojno slepi kontrolirani študiji z 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata) pri odraslih bolnikih s sočasno okužbo z virusom HIV-1 in kroničnim hepatitisom B, ki so predhodno prejemali lamivudin (študija ACTG 5127), je bila pri bolnikih, ki so bili naključno razporejeni v skupino, ki je prejemala tenofovir, povprečna serumska koncentracija HBV DNA ob izhodiščni točki 9,45 log10 kopij/ml (n = 27).
In a randomised, comparative evaluation of ramipril versus placebo for the prevention of proteinuria in kidney transplant patients converted from calcineurin inhibitors to sirolimus, a difference in the number of patients with BCAR through 52 weeks was observed [13 (9.5%) vs 5 (3.2%), respectively; p = 0.073].
V randomiziranem, primerjalnem vrednotenju ramiprila in placeba za preprečevanje proteinurije pri bolnikih s presajeno ledvico, ki so prešli z zaviralcev kalcinevrina na sirolimus, so po 52 tednih opazili razliko v številu bolnikov z BCAR [13 (9,5 %) v skupini, ki je prejemala ramipril, v primerjavi s 5 (3,2 %) v skupini, ki je prejemala placebo; p = 0,073].
In a randomised, comparative phase III trial conducted by the Gynaecological Oncology Group (GOG 0179), topotecan plus cisplatin (n=147) was compared with cisplatin alone (n=146) for the treatment of histologically confirmed persistent, recurrent or Stage IVB carcinoma of the cervix where curative treatment with surgery and/or radiation was not considered appropriate.
Randomizirano primerjalno preskušanje III. faze, ki ga je izvedla ginekološka onkološka skupina (GOG 0179), je primerjalo topotekan in cisplatin (n = 147) s cisplatinom samim (n = 146) pri zdravljenju histološko potrjenega persistentnega rekurentnega karcinoma materničnega vratu ali karcinoma materničnega vratu v stadiju IVB, kjer kurativno zdravljenje s kirurškim posegom in/ali radiacijo ni bilo primerno.
In a randomised, comparative phase III trial conducted by the Gynaecological Oncology Group (GOG 0179), topotecan plus cisplatin (n=147) was compared with cisplatin alone (n=146) for the treatment of histologically confirmed persistent, recurrent or Stage IVB carcinoma of the cervix where curative treatment with surgery and/or radiation was not considered appropriate.
V randomiziranem primerjalnem preskušanju III. faze, ki ga je izvedla Ginekološka onkološka skupina (GOG 0179), so primerjali uporabo topotekana v kombinaciji s cisplatinom (n = 147) s samim cisplatinom (n = 146) pri zdravljenju histološko potrjenega trdovratnega ponavljajočega se karcinoma materničnega vratu ali karcinoma materničnega vratu v stadiju IVB, pri katerem kurativno zdravljenje s kirurškim posegom in/ali obsevanjem ni bilo primerno.
In a randomised, double-blind study with a total of 667 patients receiving highly emetogenic chemotherapy that included cisplatin ≥ 60 mg/m2, cyclophosphamide > 1,500 mg/m2 and dacarbazine, palonosetron 250 micrograms and 750 micrograms were compared with ondansetron 32 mg administered intravenously on Day 1.
V randomizirani, dvojno slepi študiji, v kateri je sodelovalo 667 bolnikov, ki so prejemali visoko emetogeno kemoterapijo, ki je vključevala cisplatin >60 mg/m2, ciklofosfamid >1500 mg/m2 in dakarbazin, so primerjali odmerka 250 mikrogramov in 750 mikrogramov palonosetrona v primerjavi z ondansetronom 32 mg, danim prvi dan kemoterapije.
In a randomised, double-blind, clinical trial in patients with a confirmed diagnosis of acute symptomatic DVT, fondaparinux 5 mg (body weight < 50 kg), 7.5 mg (body weight  50 kg,  100 kg) or 10 mg (body weight >100 kg) SC once daily was compared to enoxaparin sodium 1 mg/kg SC twice daily.
V randomiziranem, dvojno slepem kliničnem preskušanju pri bolnikih s potrjeno diagnozo akutne simptomatske DVT so fondaparinuks v odmerkih 5 mg (telesna masa < 50 kg), 7,5 mg (telesna masa ≥ 50 kg, ≤ 100 kg) ali 10 mg (telesna masa > 100 kg) s.c. enkrat na dan primerjali z natrijevim enoksaparinatom v odmerku 1 mg/kg s.c. dvakrat na dan.
In a randomised, double-blind, multi-centre, placebo-controlled study (AC-052-364 [EARLY]),
V randomizirani, dvojno slepi, multicentrični, s placebom nadzirani študiji (AC-052-364; EARLY) je
In a randomised, double-blind, multi-centre, placebo-controlled study (AC-052-364 [EARLY]), 185 PAH patients in WHO functional class II (mean baseline 6-minute walk distance of 435 metres) received bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily (n = 93), or placebo (n = 92) for 6 months.
V randomizirani, dvojno slepi, multicentrični, s placebom nadzirani študiji (AC-052-364; EARLY) je 185 bolnikov s PAH II. funkcijskega razreda po SZO (srednja izhodiščna vrednost 435 metrov prehojenih v 6 minutah) prejemalo bosentan 62,5 mg dvakrat na dan 4 tedne in nato 125 mg dvakrat na teden (n = 93), ali placebo (n = 92) 6 mesecev.
In a randomised, double-blind, placebo-controlled study of 4 038 CRF patients not on dialysis with type 2 diabetes and haemoglobin levels ≤ 11 g/dL, patients received either treatment with darbepoetin alfa to target haemoglobin levels of 13 g/dL or placebo (see section 4.4).
V randomizirani, dvojno slepi, s placebom nadzorovani študiji pri 4 038 bolnikih s kronično ledvično odpovedjo, ki niso potrebovali dialize, vendar so imeli sladkorno bolezen tipa 2 in koncentracijo hemoglobina ≤ 11 g/dL, so bolniki prejemali zdravljenje z darbepoetinom alfa za doseganje ciljnih koncentracij hemoglobina 13 g/dL ali placebo (glejte poglavje 4.4).
In a randomised, double-blind, placebo-controlled study of 4,038 chronic renal failure patients not on dialysis with type 2 diabetes and haemoglobin levels ≤ 11 g/dL, patients received either treatment with darbepoetin alfa to target haemoglobin levels of 13 g/dL or placebo (see section 4.4).
V randomizirani, dvojno slepi, s placebom kontrolirani študiji s 4.038 bolniki s kronično ledvično boleznijo, ki niso bili na dializi in sladkorno boleznijo tipa 2, ter koncentracijo hemoglobina ≤ 11 g/dl, so bolniki prejeli zdravljenje z darbepoetinom alfa, da bi dosegli koncentracijo hemoglobina 13 g/dl, ali placebo (glejte poglavje 4.4).
In a randomised, observer blinded clinical trial with 571 patients and a follow-up duration of 6 and 12 months, photodynamic therapy with Ameluz was tested for non-inferiority to a commercially registered cream containing 16% methyl-aminolevulinate (MAL, methyl-[5-amino-4-oxopentanoate]) and superiority over placebo.
V randomiziranem kliničnem preskušanju s slepim opazovalcem, v katerem je sodelovalo 571 bolnikov in v nadaljnjem spremljanju v obdobju od šest do dvanajst mesecev so preverjali enakovrednost fotodinamičnega zdravljenja z zdravilom Ameluz z zdravilom z dovoljenjem za promet v obliki kreme, ki vsebuje 16 % metil-aminolevulinata (MAL, metil-[5-amino-4-oksopentanoat]) in superiornost zdravila Ameluz v primerjavi s placebom.
In a randomised, open label, controlled clinical trial, chemotherapy (oxaliplatin or irinotecan) and bevacizumab were given with and without panitumumab in the first-line treatment of patients with metastatic colorectal cancer (n = 1,053 [n = 823 oxaliplatin cohort, n = 230 irinotecan cohort]).
V randomiziranem, odprtem, kontroliranem kliničnem preskušanju so v terapiji prve izbire pri bolnikih z metastatskim kolorektalnim rakom uporabljali kemoterapijo (oksaliplatin ali irinotekan) in bevacizumab s panitumumabom ali brez njega (n = 1.053 [n = 823 kohorta z oksaliplatinom, n = 230 kohorta z irinotekanom]).
In a randomised, open-label multicentre study in patients receiving Kyprolis 20/56 mg/m2 infused over 30 minutes in combination with dexamethasone (Kd, n = 464) vs bortezomib plus dexamethasone (Vd, n = 465), cases of grade 2 and higher peripheral neuropathy were reported in 6% of patients with relapsed multiple myeloma in the Kd arm, compared with 32% in the Vd arm.
Randomizirana odprta multicentrična študija je primerjala uporabo zdravila Kyprolis 20/56 mg/m2, infundiranega v 30 minutah, v kombinaciji z deksametazonom (Kd, n = 464) in uporabo kombinacije bortezomiba in deksametazona (Vd, n = 465); v tej študiji so primere periferne nevropatije 2. stopnje ali več zabeležili pri 6 % bolnikov z recidivom diseminiranega plazmocitoma v skupini Kd in pri 32 % v skupini Vd.
In a randomised, open-label trial, a total of 399 previously untreated elderly patients (age 60 to 80 years) with diffuse large B cell lymphoma received standard CHOP chemotherapy (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for eight cycles, or MabThera 375 mg/m2 plus CHOP (R-CHOP).
V randomiziranem, odprtem preskušanju je 399 predhodno nezdravljenih starejših (starih od 60 do 80 let) bolnikov z difuznim velikoceličnim B limfomom prejelo osem ciklov standardne kemoterapije CHOP (750 mg/m2 ciklofosfamida, 50 mg/m2 doksorubicina, 1,4 mg/m2 do največ 2 mg vinkristina na prvi dan ter 40 mg/m2 prednizolona na 1. do 5. dan) vsake 3 tedne 8 ciklov ali pa 375 mg/m2 zdravila MabThera in sheme CHOP (R-CHOP).
In a randomized double-blind study (BR.21; Tarceva administered as second line therapy), rash (75%) and diarrhoea (54%) were the most commonly reported adverse drug reactions (ADRs).
V randomizirani, dvojno slepi študiji (BR.21; zdravilo Tarceva v drugi liniji zdravljenja) sta bila najpogostejša neželena učinka, o katerih so poročali, kožni izpuščaj (75 %) in driska (54 %).
In a randomized placebo-controlled trial in MDS subjects treatment with romiplostim was prematurely stopped due to a numerical increase in cases of MDS disease progression to AML and transient increases in blast cell counts in patients treated with romiplostim compared to placebo.
V randomiziranem, s placebom kontroliranem preskušanju pri bolnikih z MDS so zdravljenje z romiplostimom predčasno končali, ker so imeli bolniki, ki so prejemali romiplostim, v primerjavi z bolniki, ki so prejemali placebo, povečanje števila primerov napredovanja bolezni iz MDS v AML in prehodna povečanja števila blastnih celic.
In a randomized placebo-controlled trial in MDS subjects, treatment with romiplostim was prematurely stopped due to a numerical excess of disease progression to AML and an increase in circulating blasts greater than 10% in patients receiving romiplostim.
V randomiziranem, s placebom kontroliranem preskušanju pri bolnikih z MDS so zdravljenje z romiplostimom predčasno končali, ker so imeli bolniki, ki so prejemali romiplostim številčni presežek napredovanje bolezni v AML in povečanje števila blastnih celic v obtoku za več kot 10 %.
In a randomized trial in which 767 adults and children with uncomplicated P. falciparum malaria were exposed to Eurartesim, 25% of subjects were judged to have experienced an adverse drug reaction (ADR).
V randomizirani študiji, v kateri je bilo 767 odraslih in otrok z nezapleteno malarijo P. falciparum izpostavljenih zdravilu Eurartesim, so ocenili, da je imelo 25 % oseb neželene učinke na zdravilo Eurartesim.
In a randomized, controlled study in the target population, 51 patients were treated with ChondroCelect.
V randomizirani, nadzorovani študiji ciljne populacije je bilo 51 bolnikov zdravljenih z zdravilom ChondroCelect.
In a randomized, dose-ranging trial, HIV-1–infected subjects treated with dolutegravir monotherapy (ING111521) demonstrated rapid and dose-dependent antiviral activity with mean decline in HIV-1 RNA of 2.5 log10 at day 11 for 50 mg dose.
V randomiziranem preskušanju razpona odmerkov je bilo pri preiskovancih, okuženih z virusom HIV-1, ki so prejemali monoterapijo z dolutegravirjem (ING111521), dokazano hitro in od odmerka odvisno protivirusno delovanje; povprečno zmanjšanje HIV-1 RNA je bilo pri odmerku 50 mg 11. dan 2,5 log10.
In a randomized, open-label study (SP825) in patients with early stage Parkinson’s disease, 25 patients were randomized to rotigotine treatment and 26 to ropinirole.
V randomizirani, odprti študiji (SP825) z bolniki v zgodnji fazi Parkinsonove bolezni je 25 bolnikov prejemalo rotigotin in 26 ropinirol.
In a randomized, open-label study (SP825) in patients with early-stage Parkinson’s disease, 25 patients were randomized to rotigotine treatment and 26 to ropinirole.
V randomizirani, odprti študiji (SP825) z bolniki v zgodnji fazi Parkinsonove bolezni je 25 bolnikov prejemalo rotigotin in 26 ropinirol.
In a randomized, parallel, double-blind, active-controlled study, IVEMEND 150 mg (N=1,147) was compared with a 3-day aprepitant regimen (N=1,175) in patients receiving a HEC regimen that included cisplatin (≥70 mg/m2).
V randomizirani, vzporedni, dvojno slepi, z zdravilno učinkovino nadzorovani študiji so primerjali zdravilo IVEMEND 150 mg (N = 1.147) s 3-dnevnim režimom zdravljenja z aprepitantom (N = 1.175) pri bolnikih, ki so prejemali zelo emetogeno kemoterapijo, ki je vključevala cisplatin ( 70 mg/m2).
In a randomized, parallel, double-blind, placebo-controlled study, IVEMEND 150 mg (N=502) in combination with ondansetron and dexamethasone was compared with ondansetron and dexamethasone alone (control regimen) (N=498) in patients receiving a moderately emetogenic chemotherapy regimen.
V randomizirani, vzporedni, dvojno slepi, s placebom nadzorovani študiji so pri bolnikih, ki so prejemali zmerno emetogeno kemoterapijo, zdravilo IVEMEND 150 mg (N = 502) v kombinaciji z ondansetronom in deksametazonom primerjali z ondansetronom in deksametazonom samima (kontrolna shema) (N = 498).
In a rat fertility study, fertility was slightly decreased in males.
V študiji plodnosti na podganah je prišlo do rahlega zmanjšanja plodnosti pri samcih.
In a rat model on the resistance to influenza infection, an impairment of IFN-γ production was observed.
Na podganjem modelu za ugotavljanje odpornosti proti okužbi gripe so opazili oslabljeno nastajanje IFN-.
In a rat pre- and post-natal development study, pups exhibited persistent decreases in body weight at 300 mg/kg/day and higher (approximately 15 times the MRHD on a mg/m2 basis) and delayed sexual development at 600 mg/kg/day (approximately 29 times the MRHD on a mg/m2 basis).
V študiji prenatalnega in postnatalnega razvoja pri podganah so pri mladičih stalno opažali zmanjšanje telesne mase pri odmerkih 300 mg/kg/dan in več (približno 15-krat večjem odmerku od MRHD na podlagi mg/m2) in kasnejše spolno dozorevanje pri odmerkih 600 mg/kg/dan (približno 29-krat večjem odmerku od MRHD na podlagi mg/m2).
In a rat study, glycerol phenylbutyrate caused a statistically significant increase in the incidence of pancreatic acinar cell adenoma, carcinoma, and combined adenoma or carcinoma in males and females, at a dose of 4.7 and 8.4 times the dose in adult patients, (6.87 ml/m2/day based on combined AUCs for PBA and PAA).
V študiji na podganah je glicerol fenilbutirat povzročil statistično značilno zvišanje pojavnosti pankreatičnega adenoma acinarnih celic in kombiniranega adenoma ali karcinoma pri samcih in samicah pri 4,7- in 8,4-kratnem odmerku za odrasle bolnike (6,87 ml/m2/na dan na podlagi kombiniranih AUC za PBA in PAA).
In a re-reading study that increased the patient population of the pivotal study to include 38 additional autopsied patients (i.e., 106 in total), sensitivity and specificity for detection of moderate-frequent β- amyloid neuritic plaque density in the primary analysis were 91% (95% CI: 82% to 96%) and 90% (95% CI: 74% to 98%), respectively, based on the majority read (i.e., the image interpretation reached by at least 3 of the 5 readers after electronic training).
V študiji vnovičnega odčitavanja, v kateri je bila populacija bolnikov klinični študiji, ki podpira vlogo za pridobitev dovoljenja za promet povečana, da je bilo vključenih dodatnih 38 bolnikov, pri katerih je bila opravljena obdukcija (tj. skupno 106), sta bili občutljivost in specifičnost za določitev zmerne- pogoste gostote β-amiloidninih nevritičnih leh v primarni analizi 91 % (95 % IZ: 82 % do 96 %) oziroma 90 % (95 % IZ: 74 % do 98 %) pri večini odčitavanj slik (tj. interpretacija slik je bila dosežena pri vsaj 3 od 5 odčitovalcev po opravljenem usposabljanju v elektronski obliki).
In a recent publication updated information from 6 of these 11 patients revealed that all these patients remained in cytogenetic remission (range 32-38 months).
Nedavno objavljeni dopolnjeni podatki za 6 od teh 11 bolnikov razkrivajo, da so vsi ti bolniki ostali v citogenetični remisiji (po 32-38 mesecih).
In a relapse prevention study, patients responding to 12-weeks of acute treatment with open-label Cymbalta 60 mg once daily were randomised to either Cymbalta 60 mg once daily or placebo for a further 6-months.
V študiji preprečevanja relapsa so bolnike, ki so se odzvali na 12-tedensko akutno zdravljenje z znanim zdravilom Cymbalta 60 mg enkrat na dan, naključno razporedili v skupini, kjer so nadaljnjih 6 mesecev prejemali ali zdravilo Cymbalta 60 mg enkrat na dan ali placebo.
In a relapse prevention study, patients responding to 12-weeks of acute treatment with open-label duloxetine 60 mg once daily were randomised to either duloxetine 60 mg once daily or placebo for a further 6-months.
V študiji preprečevanja relapsa so bolnike, ki so se odzvali na 12-tedensko akutno zdravljenje z duloksetinom 60 mg enkrat na dan, naključno razporedili v skupini, kjer so nadaljnjih 6 mesecev prejemali ali duloksetin 60 mg enkrat na dan ali placebo.
In a relapse prevention study, patients responding to 12-weeks of acute treatment with open-label Duloxetine Lilly 60 mg once daily were randomised to either Duloxetine Lilly 60 mg once daily or placebo for a further 6-months.
V študiji preprečevanja relapsa so bolnike, ki so se odzvali na 12-tedensko akutno zdravljenje z znanim zdravilom Duloxetine Lilly 60 mg enkrat na dan, naključno razporedili v skupini, kjer so nadaljnjih 6 mesecev prejemali ali zdravilo Duloxetine Lilly 60 mg enkrat na dan ali placebo.
In a relapse prevention study, patients responding to 6 months of acute treatment with open-label Duloxetine Lilly were randomised to either Duloxetine Lilly or placebo for a further 6-months.
V študiji preprečevanja relapsa so bolnike, ki so se odzvali na 6-tedensko akutno zdravljenje z znanim zdravilom Duloxetine Lilly, naključno razporedili v skupini, kjer so nadaljnjih 6 mesecev prejemali ali zdravilo Duloxetine Lilly ali placebo.
In a relapse prevention study, patients responding to 6 months of acute treatment with open-label Xeristar were randomised to either Xeristar or placebo for a further 6-months.
V študiji preprečevanja relapsa so bolnike, ki so se odzvali na 6-tedensko akutno zdravljenje z znanim zdravilom Xeristar, naključno razporedili v skupini, kjer so nadaljnjih 6 mesecev prejemali ali zdravilo Xeristar ali placebo.
In a relative bioavailability study in adults, the eltrombopag powder for oral suspension delivered 22% higher plasma AUC(0-) than the tablet formulation.
V študiji relativne biološke uporabnosti pri odraslih je bila pri uporabi praška za peroralno suspenzijo AUC(0-) v plazmi za 22 % večja kot pri uporabi tablet.
In a renal impairment study AUC of enfuvirtide was increased on average by 43-62% in patients with severe or end stage renal disease compared to patients with normal renal function.
Rezultati študije pri bolnikih z okvaro ledvic so pokazali, da je bil AUC enfuvirtida pri bolnikih s hudo okvaro ledvic ali končno ledvično odpovedjo povečan v povprečju za 43 – 62 % v primerjavi z bolniki z normalno ledvično funkcijo.
In a renal impairment study, bosutinib exposures were increased in subjects with moderately and severely impaired renal function.
V študiji okvare ledvic so pri preiskovancih z zmerno in hudo okvaro delovanja ledvic povečevali izpostavljenost bosutinibu.
In a repeat-dose toxicity studies in rats and dogs, effects on the central and autonomic nervous system, increased liver and kidney weights and cardiac effects (second degree atrioventricular block) were seen.
V študijah toksičnosti pri ponavljajočih se odmerkih na podganah in psih so ugotovili učinke na osrednji ali avtonomni živčni sistem, povečanje mase jeter in ledvic ter učinke na srce (atrioventrikularni blok II. stopnje).
In a repeated dose study in adult patients with Sickle Cell Syndrome approximately 60% of the hydroxycarbamide dose was detected in urine at steady state.
V študiji s ponavljajočim odmerkom pri odraslih bolnikih s srpasto celičnim sindromom so približno 60 % hidroksikarbamida odkrili pri vzpostavljenem ravnotežju zdravila v urinu.
In a retrospective analysis of pooled clinical studies with Viramune immediate-release tablets, women had a three fold higher risk than men for symptomatic, often rash-associated, hepatic events (5.8 % versus 2.2 %), and treatment- naïve patients of either gender with detectable HIV-1 RNA in plasma with higher CD4 counts at initiation of nevirapine therapy were at higher risk for symptomatic hepatic events with nevirapine.
V retrospektivni analizi zbirnih kliničnih študijah zdravila Viramune tablete s takojšnjim sproščanjem je pri ženskah tveganje simptomatskih jetrnih dogodkov z nevirapinom, ki jih pogosto spremlja izpuščaj, trikrat večje kot pri moških (5,8 % proti 2,2 %), pri prvič zdravljenih bolnikih obeh spolov, ki imajo v plazmi izmerljivo raven HIV-1RNA in pri bolnikih z večjim številom celic CD4 je na začetku zdravljenja z nevirapinom bilo povečano tveganje simptomatskih jetrnih dogodkov.
In a retrospective analysis of pooled clinical studies with Viramune immediate-release tablets, women had a three fold higher risk than men for symptomatic, often rash-associated, hepatic events (5.8% versus 2.2 %), and treatment- naïve patients of either gender with detectable HIV-1 RNA in plasma with higher CD4 counts at initiation of nevirapine therapy were at higher risk for symptomatic hepatic events with nevirapine.
V retrospektivni analizi zbirnih kliničnih študijah zdravila Viramune tablete s takojšnjim sproščanjem je pri ženskah tveganje simptomatskih jetrnih dogodkov z nevirapinom, ki jih pogosto spremlja izpuščaj, trikrat večje kot pri moških (5,8 % proti 2,2 %), pri prvič zdravljenih bolnikih obeh spolov, ki imajo v plazmi izmerljivo raven HIV-1RNA in pri bolnikih z večjim številom celic CD4 je na začetku zdravljenja z nevirapinom bilo povečano tveganje simptomatskih jetrnih dogodkov.
In a retrospective analysis of the MOTIVATE studies with a more sensitive assay for screening of tropism (Trofile ES), the response rates (<50 copies/mL at week 48) in patients with only CCR5-tropic virus detected at baseline was 48.2% in those treated with maraviroc + OBT (n=328), and 16.3% in those treated with placebo + OBT (n=178).
V retrospektivni analizi študij MOTIVATE z občutljivejšim preskusom presejalnega testa tropizma (Trofile ES), je bil delež odziva 48,2 % pri bolnikih ( < 50 kopij/ml po 48 tednih), pri katerih so ob začetku raziskave ugotovili samo CCR5-tropni virus in so jih zdravili z maravirokom + OOT (n=328), pri bolnikih, ki so prejemali samo OOT (n=178), pa je bil delež odziva 16,3%.
In a retrospective analysis of the MOTIVATE studies with a more sensitive assay for screening of tropism (Trofile ES), the response rates (<50 copies/mL at week 48) in patients with only CCR5-tropic virus detected at baseline was 48.2% in those treated with maraviroc + OBT (n=328), and 16.3% in those treated with placebo + OBT (n=178).
V retrospektivni analizi študij MOTIVATE z občutljivejšim preskusom presejalnega testa tropizma (Trofile ES), je bil delež odziva 48,2 % pri bolnikih (< 50 kopij/ml po 48 tednih), pri katerih so ob začetku raziskave ugotovili samo CCR5-tropni virus in so jih zdravili z maravirokom + OOT (n=328), pri bolnikih, ki so prejemali samo OOT (n=178), pa je bil delež odziva 16,3%.